Compare American Electric Power Company Inc (AEP) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs Summit Therapeutics Inc — how do they compare? American Electric Power Company Inc trades at $123.69 (market cap $67.28B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: American Electric Power Company Inc is far larger — about 5.6× Summit Therapeutics Inc's market cap, and American Electric Power Company Inc pays a 3.07% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AEP | SMMT | |
|---|---|---|
Market Cap | $67.28B | $12.06B |
Sector | Utilities | Health |
52-Week High | $138.69 | $26.98 |
52-Week Low | $106.44 | $12.55 |
Enterprise Value | $120.17B | $11.39B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $124.17, up 1.08% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS missed estimates at $1.36 versus $1.48 expected, yet revenue grew 7% year-over-year. The company raised 2026 operating EPS guidance to $6.25–$6.55, supported by a $78 billion capital plan and 69 GW of contracted load growth. Analyst consensus is bullish with a $140.89 price target, and dividends remain stable with a $0.95 payment scheduled for September 2026.
Outlook is positive due to robust demand from data centers and regulatory progress, but risks include high debt levels and interest expenses. The stock offers growth potential from AI-driven electricity demand, though valuation premiums and execution risks warrant caution. Near-term support lies at $121, with resistance at $126.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
